Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine if intravitreal infliximab is a safe and effective treatment for macular edema secondary to uveitis.


Clinical Trial Description

Participants with uveitic macular edema will be treated with one injection of intravitreal infliximab (2.0mg/0.05ml) and followed for three months. Outcomes that be assessed include best-corrected visual acuity, macular thickness as measured by optical coherence tomography, and electroretinogram responses. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00958906
Study type Interventional
Source Icahn School of Medicine at Mount Sinai
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date August 2009
Completion date October 2009

See also
  Status Clinical Trial Phase
Completed NCT05791695 - A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
Completed NCT01384266 - A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery N/A
Active, not recruiting NCT04914884 - Intraocular Fluid Detection in Endophthalmitis
Completed NCT05657158 - Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion